GeoVax CEO to Present at ROTH Healthcare Conference, Highlighting Vaccine and Cancer Therapy Pipeline

GeoVax Labs, Inc. announced that Chairman and CEO David Dodd will participate in the 4th Annual ROTH Healthcare Opportunities Conference on October 9, 2025, at the Yale Club in New York City. The invite-only event connects healthcare companies with institutional investors through one-on-one meetings and panel discussions, providing a platform for executives to share company strategies and progress.

Dodd will be available throughout the day to discuss GeoVax's clinical pipeline, which includes three key programs. GEO-MVA, an MVA-based Mpox and smallpox vaccine, recently received favorable Scientific Advice from the European Medicines Agency and is positioned to support global preparedness and stockpile strategies. The company anticipates progressing directly to Phase 3 clinical evaluation based on recent EMA regulatory guidance, potentially accelerating development timelines.

The company's multi-antigen COVID-19 vaccine, GEO-CM04S1, is currently being evaluated in three Phase 2 clinical trials across various patient populations. These trials include immunocompromised individuals, patients with chronic lymphocytic leukemia, and healthy adults who previously received mRNA vaccines. The vaccine aims to address limitations of current COVID-19 vaccines, particularly for vulnerable populations where existing vaccines may be insufficient.

In oncology, GeoVax is developing Gedeptin, a gene-directed enzyme prodrug therapy for solid tumors. The company has completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers and plans to initiate a Phase 2 trial. This therapeutic approach represents an innovative strategy for treating challenging solid tumors where current treatment options remain limited.

The ROTH conference format consists of 25-minute management-investor meetings designed to provide institutional clients with extensive interaction opportunities and in-depth insights into company strategies and upcoming milestones. For more information about GeoVax's clinical trials and technology platform, visit https://www.geovax.com.

GeoVax's participation in this prestigious healthcare investment conference highlights the significance of their clinical pipeline and the potential impact of their vaccine and immunotherapy platforms. The company's focus on addressing unmet medical needs in infectious diseases and oncology represents important advancements in public health preparedness and cancer treatment. Their multi-antigen vaccine approach could provide more robust and durable protection against evolving pathogens, while their oncology platform offers new hope for patients with solid tumors that have limited treatment options.

The favorable regulatory feedback from EMA regarding GEO-MVA suggests potential for accelerated development and deployment of Mpox and smallpox countermeasures, which is particularly relevant given recent global health concerns. Similarly, the ongoing COVID-19 vaccine trials address critical gaps in current vaccination strategies, especially for immunocompromised populations who remain at elevated risk. The company's strong intellectual property portfolio and worldwide rights to their technologies position them for potential global impact across multiple therapeutic areas.